CC
MRTX

Casdin Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Casdin Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100,000
Closed -$4.53M – 49
2022
Q4 		$4.53M Hold
100,000
– – 0.35% 36
2022
Q3 		$6.98M Buy
+100,000
New +$7.4M 0.46% 27

Other funds holding MRTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Casdin Capital's MRTX Position: Q4 2023 in Review

Casdin Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 498,427 shares — an estimated $21.7M sold.

Casdin Capital first reported a position in MRTX in Q1 2022 and held it in 7 quarters. The position peaked at $21.7M in Q3 2023. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Casdin Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Casdin Capital sold 498,427 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $21.7M.
  • Casdin Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2022 and held it in 7 quarters.
  • Casdin Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $21.7M in Q3 2023.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Casdin Capital's 13F filing for Q4 2023, filed 14 Feb 2024.